Literature DB >> 29632181

PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression.

Bastian Dörsam1, Nina Seiwert1,2, Sebastian Foersch3, Svenja Stroh1, Georg Nagel1, Diana Begaliew1, Erika Diehl1, Alexander Kraus1, Maureen McKeague4, Vera Minneker5, Vassilis Roukos5, Sonja Reißig6, Ari Waisman6, Markus Moehler7, Anna Stier8, Aswin Mangerich8, Françoise Dantzer9, Bernd Kaina1, Jörg Fahrer10,2.   

Abstract

Colorectal cancer (CRC) is one of the most common tumor entities, which is causally linked to DNA repair defects and inflammatory bowel disease (IBD). Here, we studied the role of the DNA repair protein poly(ADP-ribose) polymerase-1 (PARP-1) in CRC. Tissue microarray analysis revealed PARP-1 overexpression in human CRC, correlating with disease progression. To elucidate its function in CRC, PARP-1 deficient (PARP-1-/-) and wild-type animals (WT) were subjected to azoxymethane (AOM)/ dextran sodium sulfate (DSS)-induced colorectal carcinogenesis. Miniendoscopy showed significantly more tumors in WT than in PARP-1-/- mice. Although the lack of PARP-1 moderately increased DNA damage, both genotypes exhibited comparable levels of AOM-induced autophagy and cell death. Interestingly, miniendoscopy revealed a higher AOM/DSS-triggered intestinal inflammation in WT animals, which was associated with increased levels of innate immune cells and proinflammatory cytokines. Tumors in WT animals were more aggressive, showing higher levels of STAT3 activation and cyclin D1 up-regulation. PARP-1-/- animals were then crossed with O6-methylguanine-DNA methyltransferase (MGMT)-deficient animals hypersensitive to AOM. Intriguingly, PARP-1-/-/MGMT-/- double knockout (DKO) mice developed more, but much smaller tumors than MGMT-/- animals. In contrast to MGMT-deficient mice, DKO animals showed strongly reduced AOM-dependent colonic cell death despite similar O6-methylguanine levels. Studies with PARP-1-/- cells provided evidence for increased alkylation-induced DNA strand break formation when MGMT was inhibited, suggesting a role of PARP-1 in the response to O6-methylguanine adducts. Our findings reveal PARP-1 as a double-edged sword in colorectal carcinogenesis, which suppresses tumor initiation following DNA alkylation in a MGMT-dependent manner, but promotes inflammation-driven tumor progression.

Entities:  

Keywords:  DNA repair; PARP-1; colorectal carcinogenesis; intestinal inflammation; mouse models

Mesh:

Substances:

Year:  2018        PMID: 29632181      PMCID: PMC5924876          DOI: 10.1073/pnas.1712345115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

Review 1.  Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development.

Authors:  Maximilian J Waldner; Markus F Neurath
Journal:  Semin Immunol       Date:  2014-01-18       Impact factor: 11.130

2.  PARP inhibition reduces acute colonic inflammation in rats.

Authors:  Susana Sánchez-Fidalgo; Isabel Villegas; Antonio Martín; Marina Sánchez-Hidalgo; Catalina Alarcón de la Lastra
Journal:  Eur J Pharmacol       Date:  2007-02-08       Impact factor: 4.432

3.  In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy.

Authors:  C Becker; M C Fantini; S Wirtz; A Nikolaev; R Kiesslich; H A Lehr; P R Galle; M F Neurath
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

4.  Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice.

Authors:  F J Oliver; J Ménissier-de Murcia; C Nacci; P Decker; R Andriantsitohaina; S Muller; G de la Rubia; J C Stoclet; G de Murcia
Journal:  EMBO J       Date:  1999-08-16       Impact factor: 11.598

5.  High resolution colonoscopy in live mice.

Authors:  C Becker; M C Fantini; M F Neurath
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 6.  Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?

Authors:  S Shall; G de Murcia
Journal:  Mutat Res       Date:  2000-06-30       Impact factor: 2.433

7.  Analysis of pyridyloxobutyl DNA adducts in F344 rats chronically treated with (R)- and (S)-N'-nitrosonornicotine.

Authors:  Yanbin Lao; Nanxiong Yu; Fekadu Kassie; Peter W Villalta; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2007-02       Impact factor: 3.739

Review 8.  Colorectal cancer.

Authors:  Ernst J Kuipers; William M Grady; David Lieberman; Thomas Seufferlein; Joseph J Sung; Petra G Boelens; Cornelis J H van de Velde; Toshiaki Watanabe
Journal:  Nat Rev Dis Primers       Date:  2015-11-05       Impact factor: 52.329

Review 9.  O6-methylguanine-DNA methyltransferase in the defense against N-nitroso compounds and colorectal cancer.

Authors:  Jörg Fahrer; Bernd Kaina
Journal:  Carcinogenesis       Date:  2013-08-08       Impact factor: 4.944

10.  Blockade of Poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis.

Authors:  B Zingarelli; C Szabó; A L Salzman
Journal:  Gastroenterology       Date:  1999-02       Impact factor: 22.682

View more
  28 in total

Review 1.  Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies.

Authors:  Yi Zhu; Jiaqi Liu; Joun Park; Priyamvada Rai; Rong G Zhai
Journal:  Pharmacol Ther       Date:  2019-04-08       Impact factor: 12.310

2.  Switching off DNA repair-how colorectal cancer evades targeted therapies through adaptive mutability.

Authors:  Jörg Fahrer
Journal:  Signal Transduct Target Ther       Date:  2020-02-21

Review 3.  Regulated cell death (RCD) in cancer: key pathways and targeted therapies.

Authors:  Fu Peng; Minru Liao; Rui Qin; Shiou Zhu; Cheng Peng; Leilei Fu; Yi Chen; Bo Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

4.  Transgelin interacts with PARP1 in human colon cancer cells.

Authors:  Zhen-Xian Lew; Hui-Min Zhou; Yuan-Yuan Fang; Zhen Ye; Wa Zhong; Xin-Yi Yang; Zhong Yu; Dan-Yu Chen; Si-Min Luo; Li-Fei Chen; Ying Lin
Journal:  Cancer Cell Int       Date:  2020-08-03       Impact factor: 5.722

5.  Functional metabolome profiling may improve individual outcomes in colorectal cancer management implementing concepts of predictive, preventive, and personalized medical approach.

Authors:  Yu Yuan; Chenxin Yang; Yingzhi Wang; Mingming Sun; Chenghao Bi; Sitong Sun; Guijiang Sun; Jingpeng Hao; Lingling Li; Changliang Shan; Shuai Zhang; Yubo Li
Journal:  EPMA J       Date:  2022-01-27       Impact factor: 6.543

6.  ADP-ribosylation signalling and human disease.

Authors:  Luca Palazzo; Petra Mikolčević; Andreja Mikoč; Ivan Ahel
Journal:  Open Biol       Date:  2019-04-26       Impact factor: 6.411

7.  Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by Targeting p53 for Proteasomal Degradation.

Authors:  Carina Neitzel; Nina Seiwert; Anja Göder; Erika Diehl; Carina Weber; Georg Nagel; Svenja Stroh; Birgit Rasenberger; Markus Christmann; Jörg Fahrer
Journal:  Cells       Date:  2019-07-30       Impact factor: 6.600

8.  In vitro selective cytotoxicity of the dietary chalcone cardamonin (CD) on melanoma compared to healthy cells is mediated by apoptosis.

Authors:  Lena Berning; Lisa Scharf; Elif Aplak; David Stucki; Claudia von Montfort; Andreas S Reichert; Wilhelm Stahl; Peter Brenneisen
Journal:  PLoS One       Date:  2019-09-25       Impact factor: 3.240

Review 9.  Novel imaging and clinical phenotypes of CONDSIAS disorder caused by a homozygous frameshift variant of ADPRHL2: a case report.

Authors:  Hajar Aryan; Ehsan Razmara; Dariush Farhud; Marjan Zarif-Yeganeh; Shaghayegh Zokaei; Seyed Abbas Hassani; Mahmoud Reza Ashrafi; Masoud Garshasbi; Ali Reza Tavasoli
Journal:  BMC Neurol       Date:  2020-08-03       Impact factor: 2.474

10.  Diagnostic and prognostic values of C‑X‑C motif chemokine ligand 3 in patients with colon cancer.

Authors:  Guo-Tian Ruan; Yi-Zhen Gong; Xi-Wen Liao; Shuai Wang; Wei Huang; Xiang-Kun Wang; Guang-Zhi Zhu; Cun Liao; Feng Gao
Journal:  Oncol Rep       Date:  2019-09-19       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.